Consolidated Balance Sheets (March 31, 2013 unaudited) (USD $)	Mar. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 19,769,013	$ 25,652,083
Short-term investments	1,286,861	2,633,944
Accounts receivable	477,180	41,896
Other current assets	1,136,042	1,078,040
Total current assets	22,669,096	29,405,963
Equipment, net	910,897	986,553
Restricted cash	1,541,842	1,577,920
Other long-term assets	61,592	39,597
Total assets	25,183,427	32,010,033
Current liabilities:
Accounts payable	1,234,575	1,523,875
Accrued expenses	3,285,022	2,410,592
Deferred revenue	3,024,565	3,314,918
Accrued warrant liability	7,553,382	4,105,659
Current portion of capital lease obligation	74,276	71,679
Total current liabilities	15,171,820	11,426,723
Noncurrent portion of capital lease obligation	78,030	97,602
Total liabilities	15,249,850	11,524,325
Stockholders' equity:
Preferred stock, $.005 par value; 10,000,000 shares authorized, 0 shares issued and outstanding as of March 31, 2013 and December 31, 2012, respectively
Common stock, $.005 par value; 80,000,000 shares authorized, 44,911,819 and 44,730,445 shares issued and outstanding as of March 31, 2013 and December 31, 2012, respectively	224,560	223,653
Additional paid-in capital	124,256,387	123,864,830
Accumulated other comprehensive income	454,281	546,473
Accumulated deficit	(128,066,112)	(118,301,789)
Total Cleveland BioLabs, Inc. stockholders' (deficit) equity	(3,130,884)	6,333,167
Noncontrolling interest in stockholders' equity	13,064,461	14,152,541
Total stockholders' equity	9,933,577	20,485,708
Total liabilities and stockholders' equity	$ 25,183,427	$ 32,010,033